Continue to slide 2 »

#10. Regeneron Pharmaceuticals, Inc. (REGN) — $10K BECAME $693,626.59

Company Name:  Regeneron Pharmaceuticals, Inc.
Sector:  Biotechnology
Growth of $10,000.00
Without Dividends Reinvested Into REGN

Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer.

Continue to slide 2 »
Start date: 04/20/2004
End date: 04/17/2024
Start price/share: $12.71
End price/share: $901.19
Dividends collected/share: $0.00
Total return: 6,990.40%
Average Annual Total Return: 23.74%
Starting investment: $10,000.00
Ending investment: $709,102.70
Years: 20.01

Presented with the assumption of reinvestment of any dividends on ex-date; historical stock values are shown adjusted for any subsequent splits.
Wise & Famous Investing Quotes
20 Largest Companies In The USA
25 Growth Stocks For 2025
10 Dividend Leaders Ready To Run
Best 5-Year Total Return Stocks
Best 10-Year Total Return Stocks
Best 2-Decade Total Return Stocks
Quotes delayed 20 minutes
Get Free SEC filing alerts for REGN:
REGN SEC Filing Email Alerts ServiceExternal link
 

Best 2-Decade Total Return Stocks - Page 1 | www.RediNews.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video.